Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Intensity Therapeutics (Nasdaq: INTS), a late-stage clinical biotechnology company developing proprietary intratumoral cancer therapies, has been named Cancer Treatment Technology Innovator of the Year 2026 – USA in GHP Magazine's Healthcare & Pharmaceutical Awards.
The judging panel cited Intensity's non-covalent drug-conjugation platform, encouraging clinical outcomes in advanced cancers with few options, and INT230-6's potential to reduce tumor burden and trigger systemic anticancer immune responses with limited off-target toxicity.
Intensity Therapeutics (Nasdaq: INTS) reported Q1 2026 results and a corporate update. Cash and cash equivalents were $10.2 million as of March 31, 2026. Preliminary INVINCIBLE-4 results showed pCR 71.4% with INT230-6 versus 33% SOC in a small sample, and 44% fewer grade ≥3 adverse events. Swissmedic approved resuming enrollment on March 26, 2026; the company plans to resume INVINCIBLE-4 enrollment in Q2 2026 and limited INVINCIBLE-3 U.S. sites by Q3 2026. First-quarter R&D was $1.2M, G&A $1.3M, and net loss $2.4M. A $60M ATM facility was established in March 2026.
Intensity Therapeutics (Nasdaq: INTS) was named a Platinum winner in the 2026 Pinnacle Awards for Healthcare in the Innovator in Biotech Solutions category on April 15, 2026.
The recognition highlights Intensity's intratumoral injection platform and lead investigational candidate INT230-6, a non-covalent drug-conjugation therapy combining cisplatin, vinblastine sulfate, and a penetration enhancer to improve tumor drug dispersion and immune recognition.
Intensity Therapeutics (Nasdaq: INTS) reported 2025 year-end results and a corporate update on March 27, 2026. The company raised over $20 million in 2025 and held $11.9 million cash, with a runway into Q2 2027. Key clinical highlights include IT-01 publication showing a 75% disease control rate and median overall survival of 11.9 months, and INVINCIBLE-4 preliminary data showing a 71.4% pCR in INT230-6 pre-SOC patients versus 33% SOC alone. Swissmedic approved resumption of INVINCIBLE-4 enrollment on March 26, 2026.
Intensity Therapeutics (Nasdaq: INTS) announced a strengthening of its intellectual property portfolio with the issuance in December 2025 of US Patent No. 12,496,345, titled "A Method of Treating Cancer."
According to the company, this brings the portfolio to four U.S. patents with one U.S. application pending, patent protection across 41 countries, and a European patent validated in 27 countries. The company highlighted registered trademarks, know-how, and ongoing IP generation to protect its intratumoral drug‑conjugation technology and lead compound INT230‑6.
Intensity Therapeutics (Nasdaq: INTS) reported preliminary INVINCIBLE-4 presurgical TNBC results through March 2, 2026. Fourteen patients have been treated (7 per cohort) of a planned 61. Cohort A (INT230-6 + SOC) showed pCR in 5/7 (71.4%) vs 2/6 (33%) in SOC alone; one SOC patient remains unevaluated.
A protocol amendment to Swissmedic and the Swiss Ethics Committee was submitted to resume enrollment after a September 2025 pause for skin irritations; Cohort A showed 44% fewer grade 3+ AEs versus SOC.
Intensity Therapeutics (Nasdaq: INTS) announced it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share. Nasdaq confirmed the company met the requirement for 10 consecutive business days from February 19, 2026 through March 4, 2026, and the matter is now closed.
Intensity Therapeutics (Nasdaq: INTS) announced a 1-for-25 reverse stock split effective 4:01 p.m. ET on February 18, 2026, with post-split trading to begin February 19, 2026 under the existing ticker INTS.
The split reduces outstanding shares from ~63,346,579 to ~2,533,863, adjusts option/warrant conversion terms proportionally, preserves total authorized shares, and provides cash in lieu of fractional shares.
The company said the Reverse Split aims to raise the per-share trading price to regain compliance with Nasdaq’s minimum bid price requirement.
Saia (NASDAQ: SAIA) announced that its logistics arm LinkEx will operate as Saia Logistics, effective the week of Jan 15, 2026. The change consolidates Saia’s freight and logistics services under one brand to simplify customer experience and reflect integrated operations between the carrier’s LTL network and logistics capabilities. The announcement states this is a brand alignment only with no changes to ownership, service, pricing, contracts, or day-to-day operations; customers retain the same contacts and processes. Saia LTL Freight operates 213 terminals nationwide and the company offers a full suite of services including truckload, expedited, warehousing, final mile, international, and integrated logistics.
Intensity Therapeutics (Nasdaq: INTS) reviewed 2025 progress and outlined 2026 priorities focused on clinical development and capital discipline. Key 2025 highlights include a peer-reviewed publication reporting a 75% disease control rate and median overall survival of 11.9 months (and 21.3 months in a sarcoma subset), Phase 2 INVINCIBLE-4 safety observations with 50% fewer grade 3+ adverse events versus neoadjuvant chemo in early data, and initiation of a protocol amendment to revise dosing.
The company raised over $20 million in 2025, extending operating runway into Q2 2027, paused Phase 3 INVINCIBLE-3 enrollment after 21 patients due to funding, and plans to seek additional capital and partner discussions in 2026.